A Unique Candlelight Concert in the Middle of the Desert Set in the Exclusive Location of the Archaeological Site of Hegra, the UNESCO World Heritage Site
A new magical experience has just lit up in the middle of the desert. People could live a unique emotion by attending the Candlelight Concert, an atmospheric musical performance set in the archaeological site of Hegra (AlUla, Saudi Arabia), the UNESCO World Heritage Site famous for having more than 100 monumental tombs carved from rock formations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005155/en/
Hegra Candlelight Classic ph.Emad Alhusayni Balich Wonder Studio
The archaeological site, just 22 minutes far from the city of AlUla, has never been used for concerts of such intimate character.
The first concert that took place on the 24th December 2021 and the next one that will take place on the 31st December 2021 are produced by Balich Wonder Studio , the live entertainment group, leader in the creation and production of large-scale ceremonies, events and shows, brand and territorial experiences worldwide.
The audience live a full emotional experience by listening to the evocative repertoire performed live by the Stefan Lombard ensemble (piano, violin, cello and oud). The famous South African musical Director has created a suite (a collection of short musical pieces) from classic compositions to contemporary, Arab, movie soundtracks and a revised take on pop music.
More than 500 high-tech candles are the magic surrounding of these musical performances: sculpted by hand, they allow spectacular graphic patterns that emotionally enhance the special moments by blending harmoniously with the forms of the archaeological site, creating a landmark that merges the suggestions of the past and the dynamic of the contemporary.
The events exploit the latest technologies as the candles thanks to their various control possibilities, can shine all night, cozily shaping the surrounding and could reach four times the brightness of a traditional candle without burning or melting: the unique color combination allows for the same warmth as a real flame candle. In addition, its innovative algorithm can make an entire set of candles flicker differently, just like real candles would.
These two special events are exclusive occasions within the suggestive AlUla Moments Season, specifically designed for ‘Winter At Tantora’. The whole season is filled with high-end cultural, musical, wellness and arts events, as well as star-studded concerts, adventurous activities and immersive heritage experiences. BWS-KSA, the branch of the Balich Wonder Studio group based in Saudi Arabia, has been appointed by the Royal Commission for AlUla to produce multiple activities throughout the entire season that will enfold in late March.
The area and the city of AlJadidah has become an exclusive gathering spot, divided in various hubs where different cultures from all over the world, itinerant performing artists and the best of the circus arts will mix and mingle in the spirit of nomadic culture and the traditional Saudi Arabian hospitality with the aim to attract the widest audience and be inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Balich Wonder Studio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 11:30:00 EEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 08:00:00 EEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 19:27:00 EEST | Press release
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r
Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 19:00:00 EEST | Press release
Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with
Methane Electrolysis Can Decarbonize LNG/LPG Imports and Achieve EU’s Climate Targets18.8.2022 15:00:00 EEST | Press release
To become independent of Russian natural gas imports by 2027, the European Union is increasing near-term imports of US or Azerbaijan liquefied natural gas (LNG) or liquefied petroleum gas (LPG). The main element of LNG, methane, is the second leading greenhouse gas contributing to climate change. Environmental organizations warn that long-term supply contracts for the fossil LNG will undermine the European Green Deal. The German company Graforce has developed a methane electrolysis technology (plasmalysis) that uses LNG or LPG to produce hydrogen and solid carbon for dioxide-free energy generation. Compared to water electrolysis, plasmalysis requires only one fifth the energy to produce the same amount of hydrogen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005013/en/ Graforce has developed methane electrolysis plants. Errected at LNG terminals or other decentralized locations, they can decarbonize energy supply, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom